Check Cap (CHEK) Price Target Increased to $6.00 by Analysts at HC Wainwright
Check Cap (NASDAQ:CHEK) had its price target raised by investment analysts at HC Wainwright from $5.50 to $6.00 in a report issued on Thursday. The firm currently has a “buy” rating on the medical research company’s stock.
Other research analysts also recently issued research reports about the company. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Check Cap in a research note on Wednesday, September 27th. Zacks Investment Research downgraded Check Cap from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Check Cap currently has a consensus rating of “Hold” and a consensus price target of $4.75.
Check Cap (NASDAQ:CHEK) opened at $0.85 on Thursday. Check Cap has a 12 month low of $0.80 and a 12 month high of $2.55. The company has a market capitalization of $14.44 and a PE ratio of -1.39.
About Check Cap
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.